Mazereeuw, Graham
Gomes, Tara
Macdonald, Erin M.
Greaves, Simon
Li, Ping
Mamdani, Muhammad M.
Redelmeier, Donald A.
Juurlink, David N.
Funding for this research was provided by:
Canadian Institutes of Health Research
Government of Ontario
Ontario Ministry of Health and Long-Term Care
Article History
First Online: 23 April 2020
Compliance with Ethical Standards
:
: This study was supported by the Ontario Drug Policy Research Network (ODPRN), which is funded by a grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The ODPRN is also funded by the Ontario Strategy for Patient-Orientated Research (SPOR) Support Unit, which is supported by the Canadian Institutes of Health Research and the Province of Ontario. This study was also supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario MOHLTC. Datasets provided by ICES were linked using unique encoded identifiers and analyzed at ICES. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES, the SPOR Unit, or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions, and statements expressed herein are those of the author, and not necessarily those of CIHI.
: Graham Mazereeuw, Tara Gomes, Ping Li, Simon Greaves, Erin M. Macdonald, and Donald A. Redelmeier have no conflicts of interest that are directly relevant to the content of this study. Muhammad M. Mamdani has served as an advisory board member for the following pharmaceutical companies: Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Hoffman La Roche, Novartis, and Novo Nordisk. David N. Juurlink is a member of Physicians for Responsible Opioid Prescribing (PROP; ExternalRef removed), a volunteer organization with the goal of promoting safer opioid prescribing.
: The datasets generated and/or analyzed during the current study are not publicly available as some participants may be identifiable by unique demographic or medical characteristics. The datasets may be available from the corresponding author on reasonable request.